*Please note that this translation is to be used solely as reference.
In case of any discrepancy between this translation and the Japanese original, the latter shall prevail.
FY 2022 Financial Results Briefing
Monday, May 23, 2022
Kazuhiro Hatano
President and CEO
Linical Co.,Ltd.
TSE Prime 2183
Contents
1. Business Orveview | P. 2 ~ 4 |
2. Financial Results for FY ended March 2022 P. 5 ~ 15
3. Forecasts of FY ending March 2023 | P. 16 ~ 18 |
4. Management Strategy | P. 19 ~ 28 |
1. Business Overview
Global CRO from Japan
- Global Linical Network
Beijing | Canada | |||||
Korea | Illinois | |||||
Germany | ||||||
Tokyo | ||||||
Spain | Czech | Shang | San Diego | New York | ||
Republic | Osaka | |||||
Poland | France | India | hai | (Linical Headquarters) | Florida | |
Hungary | Romania | |||||
UK Netherlands | Taiwan | Mexico | ||||
Italy | Philippines | |||||
Singapore | Brazil | |||||
Indonesia | ||||||
South Africa | Australia | Chile | ||||
Argentina | ||||||
Red: Headquarters Orange: Branch Pink: Subsidiary Blue: Subsidiary Green: CRA Employment ash: Under consideration as base |
Linical aims to be a global CRO originating in Japan and contributes to new drug development as a drug | |
development professional | |
We currently operate in 18 countries and regions, and can provide services in more than 20 countries and | |
regions worldwide | 3 |
Trends in Sales and Operating Income since Establishment
- Sales and Operating Income since Establishment (Billions of Yen)
Net Sales | Operating Profit | |||
Net Sales | ||||
100 | November 2014 | |||
European CRO | ||||
Acquisition of | ||||
Nuvisan |
Operating | |||
April 2018 | 115 | Profit | |
50 | |||
U.S. CRO | |||
Accelovance | |||
Acquisition | 113 | 109 | |
10340
91
83
January 2014 | 77 | 30 | ||||||
March 2013 | ||||||||
October 2008 | Korea CRO | |||||||
First Section | P-Pro Acquisition | |||||||
50 | Mothers Listed | of the Tokyo | 20 | |||||
Stock | 49 | COVID-19 | ||||||
June 2005 | Exchange | |||||||
36 | 37 | |||||||
Establishment | ||||||||
25 | 31 | 10 | ||||||
24 | ||||||||
20 | ||||||||
1 | 13 | |||||||
0 | 6 | 0 | ||||||
(Fiscal Year) 2006/3 2007/3 2008/3 2009/3 2010/3 2011/3 2012/3 2013/3 2014/3 2015/3 2016/3 2017/3 2018/3 2019/3 2020/3 2021/3 2022/3
We achieved our highest ever sales while the impacts of COVID-19 remained in each region
Operating profit has also recovered to pre-COVID-19 levels
4
This is an excerpt of the original content. To continue reading it, access the original document here.